<- Go Home
Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Market Cap
AUD 146.8M
Volume
1.3M
Cash and Equivalents
AUD 15.4M
EBITDA
-AUD 61.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-AUD 12.1K
Profit Margin
N/A
52 Week High
AUD 0.47
52 Week Low
AUD 0.14
Dividend
N/A
Price / Book Value
41.29
Price / Earnings
-1.61
Price / Tangible Book Value
55.87
Enterprise Value
AUD 138.9M
Enterprise Value / EBITDA
-2.27
Operating Income
-AUD 61.2M
Return on Equity
456.96%
Return on Assets
-138.75
Cash and Short Term Investments
AUD 15.4M
Debt
AUD 7.5M
Equity
AUD 3.5M
Revenue
N/A
Unlevered FCF
-AUD 27.1M
Sector
Biotechnology
Category
N/A